New pill targets KRAS mutations in Hard-to-Treat cancers

NCT ID NCT06447662

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 36 times

Summary

This study tests a new experimental drug, PF-07934040, for people with advanced solid tumors that have a KRAS gene mutation. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV. The goal is to find the safest dose and see if the drug can shrink tumors or slow cancer growth. The study includes people with non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Barnes-Jewish Hospital
RECRUITING

St Louis, Missouri, 63110, United States
Beijing Cancer hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100142, China
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
RECRUITING

Duarte, California, 91010, United States
City of Hope Investigational Drug Service (IDS)
RECRUITING

Duarte, California, 91010, United States
Cleveland Clinic Taussig Cancer Center
RECRUITING

Cleveland, Ohio, 44195, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Duke University Medical Center, lnvestigational Chemotherapy Service
RECRUITING

Durham, North Carolina, 27710, United States
Highlands Oncology Group
RECRUITING

Springdale, Arkansas, 72762, United States
Highlands Oncology Group, PA
RECRUITING

Fayetteville, Arkansas, 72703, United States
Highlands Oncology Group, PA
RECRUITING

Rogers, Arkansas, 72758, United States
Miriam Hospital
RECRUITING

Providence, Rhode Island, 02906, United States
Pan American Center for Oncology Trials, LLC
RECRUITING

Rio Piedras, 00935, Puerto Rico
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Sibley Memorial Hospital
RECRUITING

Washington D.C., District of Columbia, 20016, United States
Siteman Cancer Center
RECRUITING

St Louis, Missouri, 63108, United States
Siteman Cancer Center - North County
RECRUITING

Florissant, Missouri, 63031, United States
Siteman Cancer Center - South County
RECRUITING

St Louis, Missouri, 63129, United States
Siteman Cancer Center - St Peters
RECRUITING

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center - West County
RECRUITING

Creve Coeur, Missouri, 63141, United States
University of Cincinnati Medical Center
RECRUITING

Cincinnati, Ohio, 45219, United States
University of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
RECRUITING

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion
RECRUITING

Aurora, Colorado, 80045, United States
University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)
RECRUITING

Aurora, Colorado, 80045, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States
West Chester Hospital
RECRUITING

West Chester, Ohio, 45069, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG CARCINOMA, PANCREATIC DUCTAL COLORECTAL NEOPLASMS